In Brief: BioLase
This article was originally published in The Gray Sheet
Executive SummaryBioLase: Receives marketing clearance from FDA for its LaserSpray dental laser accessory. The device allows physicians to "deliver a coolant spray of air and water to tissue sites during surgical interventions." The San Clemente, California-based firm notes that the move "will allow the company to market its proprietary Target Tissue Cooling System" and delivery systems for use with dental lasers...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.